Capricor
1D
1W
1M
3M
YTD
1Y
5Y
ALL
Why Robinhood?
Robinhood gives you the tools you need to put your money in motion. You can buy or sell Capricor and other ETFs, options, and stocks.About CAPR
Capricor Therapeutics, Inc. is a clinical-stage biotechnology company, which focuses on the development of transformative cell and exosome-based therapeutics for treating Duchenne muscular dystrophy (“DMD”), a rare form of muscular dystrophy which results in muscle degeneration and premature death, and other diseases with unmet medical needs. Its product candidate consists of CAP-1002, Engineered Exosomes, CAP-2003, and Exosome-Based Vaccine.
CEOLinda Marbán
CEOLinda Marbán
Employees160
Employees160
HeadquartersSan Diego, California
HeadquartersSan Diego, California
Founded1996
Founded1996
Employees160
Employees160
CAPR Key Statistics
Market cap277.96M
Market cap277.96M
Price-Earnings ratio-3.70
Price-Earnings ratio-3.70
Dividend yield—
Dividend yield—
Average volume1.33M
Average volume1.33M
High today$6.62
High today$6.62
Low today$6.05
Low today$6.05
Open price$6.45
Open price$6.45
Volume1.90M
Volume1.90M
52 Week high$20.75
52 Week high$20.75
52 Week low$5.68
52 Week low$5.68
CAPR News
TipRanks 15h
Capricor Therapeutics announces publication in Biomedicines on DeramiocelCapricor Therapeutics (CAPR) announced the publication in Biomedicines, an international peer-reviewed journal, describing a novel in-vitro potency assay design...
Analyst ratings
100%
of 10 ratingsBuy
100%
Hold
0%
Sell
0%
People also own
Based on the portfolios of people who own CAPR. This list is generated using Robinhood data, and it’s not a recommendation.